- Home
- SIGA vs GLUE Comparison
SIGA vs GLUE Comparison
Compare SIGA & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- GLUE
- Stock Information
- Founded
- SIGA 1995
- GLUE 2019
- Country
- SIGA United States
- GLUE United States
- Employees
- SIGA N/A
- GLUE N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- GLUE Health Care
- Exchange
- SIGA Nasdaq
- GLUE Nasdaq
- Market Cap
- SIGA 422.9M
- GLUE 283.6M
- IPO Year
- SIGA 1997
- GLUE 2021
- Fundamental
- Price
- SIGA $6.77
- GLUE $5.20
- Analyst Decision
- SIGA
- GLUE Buy
- Analyst Count
- SIGA 0
- GLUE 2
- Target Price
- SIGA N/A
- GLUE $13.50
- AVG Volume (30 Days)
- SIGA 382.0K
- GLUE 415.2K
- Earning Date
- SIGA 07-31-2025
- GLUE 08-07-2025
- Dividend Yield
- SIGA 8.70%
- GLUE N/A
- EPS Growth
- SIGA N/A
- GLUE N/A
- EPS
- SIGA 0.67
- GLUE 0.08
- Revenue
- SIGA $120,330,310.00
- GLUE $159,487,000.00
- Revenue This Year
- SIGA N/A
- GLUE $49.02
- Revenue Next Year
- SIGA $95.31
- GLUE N/A
- P/E Ratio
- SIGA $10.28
- GLUE $66.53
- Revenue Growth
- SIGA N/A
- GLUE 14889.38
- 52 Week Low
- SIGA $4.95
- GLUE $3.50
- 52 Week High
- SIGA $12.83
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- SIGA 61.28
- GLUE 64.63
- Support Level
- SIGA $6.34
- GLUE $4.42
- Resistance Level
- SIGA $7.07
- GLUE $4.85
- Average True Range (ATR)
- SIGA 0.22
- GLUE 0.24
- MACD
- SIGA 0.02
- GLUE 0.05
- Stochastic Oscillator
- SIGA 71.70
- GLUE 81.55
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.